Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C32H38Cl2N10O4 |
| Molecular Weight | 697.615 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=C(NC(=O)C2=CC(NC(=O)C3=CC(NC(=O)C4=CC=C(C=C4)N(CCCl)CCCl)=CN3C)=CN2C)C=C1C(=O)NCCC(N)=N
InChI
InChIKey=ARKYUICTMUZVEW-UHFFFAOYSA-N
InChI=1S/C32H38Cl2N10O4/c1-41-18-22(14-25(41)30(46)37-11-8-28(35)36)39-32(48)27-16-23(19-43(27)3)40-31(47)26-15-21(17-42(26)2)38-29(45)20-4-6-24(7-5-20)44(12-9-33)13-10-34/h4-7,14-19H,8-13H2,1-3H3,(H3,35,36)(H,37,46)(H,38,45)(H,39,48)(H,40,47)
| Molecular Formula | C32H38Cl2N10O4 |
| Molecular Weight | 697.615 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Tallimustine (also known as FCE 24517), an alkylating benzoyl mustard derivative of distamycin A that was studied as an anti-tumor agent. Tallimustine participated in phase I clinical trial in patients with advanced cancer. As a result, the was obtained the recommended Phase II dosage for tallimustine. However, the further development of this drug was discontinued.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer. | 1998 Jan |
|
| Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine. | 2001 Jun |
Patents
Sample Use Guides
Patients with advanced solid tumors received i.v. bolus injections of tallimustine daily for 3 consecutive days. Patients were treated at six dosage levels of 33.3 micrograms/m2/day to 250 micrograms/m2/day for 3 consecutive days, with courses of therapy repeated every 28 days
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:35:18 GMT 2023
by
admin
on
Fri Dec 15 16:35:18 GMT 2023
|
| Record UNII |
71193OXG6S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C697
Created by
admin on Fri Dec 15 16:35:18 GMT 2023 , Edited by admin on Fri Dec 15 16:35:18 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C1603
Created by
admin on Fri Dec 15 16:35:18 GMT 2023 , Edited by admin on Fri Dec 15 16:35:18 GMT 2023
|
PRIMARY | |||
|
DB15466
Created by
admin on Fri Dec 15 16:35:18 GMT 2023 , Edited by admin on Fri Dec 15 16:35:18 GMT 2023
|
PRIMARY | |||
|
115308-98-0
Created by
admin on Fri Dec 15 16:35:18 GMT 2023 , Edited by admin on Fri Dec 15 16:35:18 GMT 2023
|
PRIMARY | |||
|
71193OXG6S
Created by
admin on Fri Dec 15 16:35:18 GMT 2023 , Edited by admin on Fri Dec 15 16:35:18 GMT 2023
|
PRIMARY | |||
|
65924
Created by
admin on Fri Dec 15 16:35:18 GMT 2023 , Edited by admin on Fri Dec 15 16:35:18 GMT 2023
|
PRIMARY | |||
|
100000083205
Created by
admin on Fri Dec 15 16:35:18 GMT 2023 , Edited by admin on Fri Dec 15 16:35:18 GMT 2023
|
PRIMARY | |||
|
C066900
Created by
admin on Fri Dec 15 16:35:18 GMT 2023 , Edited by admin on Fri Dec 15 16:35:18 GMT 2023
|
PRIMARY | |||
|
SUB10807MIG
Created by
admin on Fri Dec 15 16:35:18 GMT 2023 , Edited by admin on Fri Dec 15 16:35:18 GMT 2023
|
PRIMARY | |||
|
DTXSID40151045
Created by
admin on Fri Dec 15 16:35:18 GMT 2023 , Edited by admin on Fri Dec 15 16:35:18 GMT 2023
|
PRIMARY | |||
|
CHEMBL89705
Created by
admin on Fri Dec 15 16:35:18 GMT 2023 , Edited by admin on Fri Dec 15 16:35:18 GMT 2023
|
PRIMARY | |||
|
7032
Created by
admin on Fri Dec 15 16:35:18 GMT 2023 , Edited by admin on Fri Dec 15 16:35:18 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
